Jeremy J Walsh1,2, Helena Neudorf1, Jonathan P Little1. 1. Exercise Metabolism and Inflammation Laboratory, University of British Columbia Okanagan, Kelowna, BC, Canada. 2. Department of Kinesiology, McMaster University, Hamilton, ON, Canada.
Abstract
CONTEXT: Postprandial hyperglycemia increases systemic inflammation and is a risk factor for cardiovascular disease. A ketone monoester (KME) drink containing β-hydroxybutyrate (β-OHB) rapidly lowers plasma glucose, which may be a strategy protecting against postprandial hyperglycemia. OBJECTIVE: We hypothesized that KME would attenuate 2-hour postprandial glucose, lower systemic inflammation, and improve vascular function in adults with obesity. METHODS: In a randomized crossover design, 14 participants with obesity (age = 56 ± 12 years; body mass index = 32.8 ± 7.7 kg/m2) consumed KME (12 g β-OHB) or placebo 15 minutes prior to each meal for 14 days with all meals provided and matched between conditions. Postprandial glycemia was assessed by continuous glucose monitoring. Vascular function and inflammation were assessed before and after treatment periods. RESULTS: Postprandial glucose was 8.0% lower in KME versus placebo (g = 0.735; P = 0.011) and 24-hour average glucose reduced by 7.8% (g = 0.686; P = 0.0001). Brachial artery flow-mediated dilation increased from 6.2 ± 1.5% to 8.9 ± 3.3% in KME (g = 1.05; P = 0.0004) with no changes in placebo (condition × time interaction, P = 0.004). There were no changes in plasma cytokines; however, lipopolysaccharide-stimulated monocyte caspase-1 activation was lower following KME supplementation versus placebo (stimulation × condition × time interaction; P = 0.004). The KME supplement was well tolerated by participants and adherence to the supplementation regimen was very high. CONCLUSIONS: In adults with obesity, 14 days of premeal KME supplementation improves glucose control, enhances vascular function, and may reduce cellular inflammation. KME supplementation may be a viable, nonpharmacological approach to improving and protecting vascular health in people with heightened cardiometabolic risk.
CONTEXT: Postprandial hyperglycemia increases systemic inflammation and is a risk factor for cardiovascular disease. A ketone monoester (KME) drink containing β-hydroxybutyrate (β-OHB) rapidly lowers plasma glucose, which may be a strategy protecting against postprandial hyperglycemia. OBJECTIVE: We hypothesized that KME would attenuate 2-hour postprandial glucose, lower systemic inflammation, and improve vascular function in adults with obesity. METHODS: In a randomized crossover design, 14 participants with obesity (age = 56 ± 12 years; body mass index = 32.8 ± 7.7 kg/m2) consumed KME (12 g β-OHB) or placebo 15 minutes prior to each meal for 14 days with all meals provided and matched between conditions. Postprandial glycemia was assessed by continuous glucose monitoring. Vascular function and inflammation were assessed before and after treatment periods. RESULTS: Postprandial glucose was 8.0% lower in KME versus placebo (g = 0.735; P = 0.011) and 24-hour average glucose reduced by 7.8% (g = 0.686; P = 0.0001). Brachial artery flow-mediated dilation increased from 6.2 ± 1.5% to 8.9 ± 3.3% in KME (g = 1.05; P = 0.0004) with no changes in placebo (condition × time interaction, P = 0.004). There were no changes in plasma cytokines; however, lipopolysaccharide-stimulated monocyte caspase-1 activation was lower following KME supplementation versus placebo (stimulation × condition × time interaction; P = 0.004). The KME supplement was well tolerated by participants and adherence to the supplementation regimen was very high. CONCLUSIONS: In adults with obesity, 14 days of premeal KME supplementation improves glucose control, enhances vascular function, and may reduce cellular inflammation. KME supplementation may be a viable, nonpharmacological approach to improving and protecting vascular health in people with heightened cardiometabolic risk.
Authors: Dick H J Thijssen; Mark A Black; Kyra E Pyke; Jaume Padilla; Greg Atkinson; Ryan A Harris; Beth Parker; Michael E Widlansky; Michael E Tschakovsky; Daniel J Green Journal: Am J Physiol Heart Circ Physiol Date: 2010-10-15 Impact factor: 4.733
Authors: Jane E Yardley; Ronald J Sigal; Glen P Kenny; Michael C Riddell; Leif E Lovblom; Bruce A Perkins Journal: Diabetes Technol Ther Date: 2012-11-08 Impact factor: 6.118
Authors: Niranjana Natarajan; Daijiro Hori; Sheila Flavahan; Jochen Steppan; Nicholas A Flavahan; Dan E Berkowitz; Jennifer L Pluznick Journal: Physiol Genomics Date: 2016-09-23 Impact factor: 3.107
Authors: Megan P Smorschok; Frances M Sobierajski; Graeme M Purdy; Laurel A Riske; Stephen A Busch; Rachel J Skow; Brittany A Matenchuk; Jamie R Pfoh; Emily R Vanden Berg; Andrea Linares; Kennedy Borle; Lauren Lavoie; Gurkarn Saran; Rebecca Dyck; Deanna R Funk; Trevor A Day; Normand G Boulé; Margie H Davenport; Craig D Steinback Journal: Appl Physiol Nutr Metab Date: 2018-09-18 Impact factor: 2.665
Authors: Roni Nielsen; Niels Møller; Lars C Gormsen; Lars Poulsen Tolbod; Nils Henrik Hansson; Jens Sorensen; Hendrik Johannes Harms; Jørgen Frøkiær; Hans Eiskjaer; Nichlas Riise Jespersen; Søren Mellemkjaer; Thomas Ravn Lassen; Kasper Pryds; Hans Erik Bøtker; Henrik Wiggers Journal: Circulation Date: 2019-04-30 Impact factor: 29.690
Authors: Madison L Kackley; Milene L Brownlow; Alex Buga; Chris D Crabtree; Teryn N Sapper; Annalouise O'Connor; Jeff S Volek Journal: Front Neurosci Date: 2022-09-30 Impact factor: 5.152
Authors: Oliver Chen; Traci M Blonquist; Eunice Mah; Kristen Sanoshy; Dawn Beckman; Kristin M Nieman; Barbara L Winters; Joshua C Anthony; Eric Verdin; John C Newman; Brianna J Stubbs Journal: Nutrients Date: 2021-06-16 Impact factor: 5.717